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ABSTRACT 
Bioavailability is mostly effected by drug dissolution and its release from the dosage form, and it mainly depends on solubility of drug. For the 
development of new pharmaceutical  products the major issue any pharmaceutical industry faces is solubility that ultimately results in low 
bioavailability. To enhance the solubility of poorly soluble drugs liquisolid compacts is one of the impending techniques. This technique 
involves a preparation where the liquid drug present in the form of a solution or suspension is transformed into a non sticky, dry, compactable, 
free-flowing powders, this is accomplished by adding certain coating agents and carriers that are appropriate. This technique with  comparison 
to conventional tablets has the capability of enhancing the absorption of less soluble drugs in its molecularly dispersed form, rate of dissolution, 
aqueous solubility thereby increasing its bio availability by using less production costs and simpler manufacturing processes. 
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Introduction 
The main criteria taken into consideration before deciding 
the dosage form is solubility of an active compound. The 
number of drugs with poor solubility has increased due to 
the recent developments in high-throughput screening and 
combinatorial chemistry[1].The newly developed drugs 
which are given for oral administration half of them are 
poorly soluble in water which affects the formulation 
development process. Many hydrophobic drugs have less 
dissolution in the gastrointestinal tract hence show 
incomplete or erratic absorption of the drug. Drugs falling 
under the biopharmaceutical classification system (BCS) 
class II have low solubility and dissolution rate compared to 
other class of drugs hence have less bioavailability. This low 
solubility and dissolution rate cane overcome as well as 
enhanced using a few common methods like micro 
ionization, lyophilisation, solid dispersion, co-solvency and 
complexing agents. Out of these the liquisolid compact 
technique found to be the best to enhance the bioavailability 
of the class II drugs of BCS. This technique is also called as 
powder solution technology. The process involves a 
preparation prepared by converting a suspension or a 
solution form of drug into a non-sticky, dry, compressible 
free flowing powder which is prepared by adding a few 
designated carriers and coating agents to the liquid form of 
drug. Using liquisolid technique, delivered an increment in 
the drug dissolution profile as a result of increased wetting 
properties and surface area. Unfortunately this method is 
confined to drugs with low dose and less solubility. The 
carriers used in the compacts should have a great adsorption 
property and should show absorption when added to the 
liquid medication[2]. The most commonly used carrier is 
microcrystalline cellulose. The uses of the coating material 
include covering the surface, imparting flowability to 
powder, providing content uniformity to the manufactured 
tablet dosage form. Other factors like water solubility, wet 
ability and rate of release of drug can be incremented by 
using disintegrants. This technique uses non-volatile 
solvents that are water miscible and can impart binding 
action. 
Advantages 
 The liquisolid compacts are very flexible as they are 
used for poorly soluble drugs. 
 The bioavailability of oral drugs which are insoluble in 
water is increased. 
 The cost of manufacturing is cheap compared to soft 
gelatin. 
 The drug can be formulated in many ways where it is 
present in a solubilised form that can increase the 
wetting property and improves drug release profile. 
 Depending upon the character of the carriers used 
instant release or continual release dosage forms can 
be prepared into liquisolid compacts. 
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 Using certain hydrophobic carriers and surface active 
agents can increase the drug release and wetting 
respectively thereby increases the dissolution profile. 
 The manufacturing efficiency and the techniques can 
be improved. 
 The extent of absorption is increased up to 15% more 
that the conventional tablets. 
Limitations 
 As it is used only for low dose water insoluble drugs it 
cannot be used in the preparation of high dose water 
insoluble drugs. 
 The weight of the tablet is increased due to the 
addition of carrier and coating material. 
 Mathematical calculations must be applied[3-5]. 
 Drug release can be enhanced by adding substances 
with greater absorption rate but this results in a 
decreased tablet size. 
 If the acceptable compression is not achieved it results 
in inadequate hardness of the product. 
 The bioavailability and rate of dissolution are 
dependent on solubility of the drug in a non-volatile 
liquids. 
Theoretical Facts in the Liquisolid System 
A sufficient quantity of the liquid only should be added as 
the powder looses its flowability and compression 
properties if it exceeds. The maximum retention potential of 
powder with acceptable flow can be estimated by two 
mathematical approaches given by Spireas, they are ɸ value 
and excipients ratio. Flowability can be calculated by rate of 
flow or angle of repose. The compressible nature of the 
powder along with the maximum liquid retention potential 
can be calculated by ψ number. Excipient ratio is known as 
the ratio of weight of carrier to the coating agent[6]. 
                                             ER = C/CA 
This excipient ratio is mainly dependent on the liquid 
carrier. A liquid system with sufficient compressibility and 
flowability is possible only when the load of liquid on carrier 
material is not over the required limit. This is given by liquid 
load factor(LLf) which is a ratio of weight of liquid 
formulation (W) to carrier material(C). 
                                               LLf = W/C 
Adequate flow behaviour (ɸLLf) is attained by this liquid 
load factor(LLf) 
                                            ɸLLf = ɸ + ψ.(1/ER) 
the satisfactory compatibility (ψLLf) for a liquisolid system 
can also be determined as                                                                
ψLLf = ψ + ψ.(1/ER). 
Either ɸLLf or ψLLf (whichever has lesser magnitude) is the 
optimum liquid load factor (LLo) required to get an 
acceptable compressibility and flow behaviour of the system. 
As soon as the Llo is measured, the sufficient amounts of 
coating agent and carrier required for the liquid formulation 
to convert into a compactable, free flowing system can be 
calculated as  
                 AC = W/Llo                           AC = AC/ER 
Mechanism Involved In Improved Drug Release 
Profile from Liquisolid Systems 
Different research reports accentuated that the release rate 
of poorly soluble and less dose drugs is increased by the 
liquisolid technique. Additives like polyvinyl pyrrolidine 
(PVP), hydroxyl propyl methyl cellulose (HPMC), polyethene 
glycol 35000 (PEG) can be added in order to incorporate a 
high dose water insoluble drugs, and also to enhance coating 
and carrier material absorption capacity. The mechanisms 
utilized to increase the drug release are 
Augmented Surface Area 
When there is a complete dissolution of the drug in the 
liquid vehicle in liquisolid system results in an increased 
surface are of drug and also indicate that the drug is in a 
molecularly dispersed state and in  solubilised form. 
The drug release from the tablets prepared by liquisolid 
technique is at high rate this was confirmed by a comparison 
between directly compressed tablets and tablets from this 
technique. Dividing the solubility of drug by concentration of 
drug gives the fraction molecularly dispersed drug. 
                                                      Fm = S/C 
                                         Where, 
                                                      Fm = 1 S≥C 
Improved Aqueous Solubility Of Drug 
A solid liquid boundary present in between the liquisolid 
primary particles and the media around it increases the 
drugs water solubility[8]. The amount of vehicle that gets 
diffused along with the drug particles also plays a role in the 
enhancement of aqueous solubility which can be mainly due 
to co-solvent effect. 
Improved Wetting Properties 
Wetting of primary particles is due to reduced surface 
tension which is a result of surface active properties present 
in the liquid vehicle, water rising time and contact angle 
measurement are the methods used for determining wet 
ability. 
Porosity 
As stated by Pezzini et al liqusolid technology lead to the 
production of soft substances with increased porosity that 
augmented both disintegration and dissolution processes. 
Mechanism of Sustained Drug Release from 
Liquisolid Systems 
A simple substitution of hydrophobic carrier in the place of a 
hydrophilic carrier reduces the wetting thereby reducing 
disintegration and thus prolongs the drug release. 
Processing of liquisolid compacts does not show any change 
in crystalline nature or complex formation of the drug. These 
studies are confirmed by X-ray crystallography and DSC 
measurements[9]. The drug release can also be reduced by 
the effect of liquid vehicle which can be confirmed from the 
comparative study between directly compressed and 
liquisolid prepared tablets. Liquisolid compacts have less or 
reduced coalescence with polymer particles compared to 
traditional matrix tablets this may also be a reason for 
decreased drug release leading to reduced porosity an 
increase in tortuosity. For the sustained release of drug 
hydrophobicity plays a major role . 
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Formulation of Liquisolid Compacts 
Carriers, binding agents, non-volatile solvents, disintegrants, 
coating materials, lubricants are used in the formulation of 
liquisolid compacts. 
Carrier materials 
The carrier materials should maintain flowability and 
compressibility, should be spongy in nature and must have 
required absorption properties both carrier and coating 
material should posses only a limited water quantity. Eg: 
microcrystalline cellulose(MCC). 
Coating Materials 
They are generally coarse powdered materials that help in 
covering the particles which have been wet by adsorbing of 
the liquid in excess amounts thereby producing a dry free 
flowing powder. 
Non-Volatile Solvents 
Non volatile, inert and not extremely viscous solvents are 
used in the formulation, they must also posses high boiling 
point and good solubilisation power. These liquids also 
provide binding action. Eg: glycine, polysorbate 80, 
propylene glycol, polyethylene glycol200 and 400. 
Disintegrating Agents 
Use of these agents increases wet ability, drug release rate 
and water solubility as they take in water. They play a role in 
breaking the compacts into smaller particles. Eg: sodium 
starch glycolate and cross povidene, explotab and 
pregelatinized starch. 
Drug Candidate 
Less soluble drugs like BSC class II drugs and class-IV drugs 
used as drug candidates for this technique this provides 
increased water solubility of these drugs. Eg: g-naproxen, 
digitoxin, bednisolone, hydrocortisone, ketoprofen[10]. 
 Methodology 
The needed amounts of the drug candidate and given 
amount of non-volatile solvent is weighed and then added, 
the mixture is agitated, subjected to heat if necessary. This 
produces a drug solution and to this solution carrier particle 
and coating materials are added. The process of mixing 
should be done in three stages format as stated by Spireas et 
al 
First Stage 
The elements which are weighed were mixed at a measured 
mixing rate of one rotation / second or minute, that can help 
the aqueous medicament to devote its part in the powder. 
Second Stage 
The thorough absorption of the drug solution into the 
powder particle voids takes place when the mixture from the 
first stage id spread uniformly on a mortar surface for about 
5min. 
Third Stage 
The final blend accessible for compression is produced when 
the blend formed from the above stage is agitated with a 
super disintegrate for 30 sec at a blending speed. 
Preformulation Studies 
The physiochemical characteristics can be confirmed by the 
preformulations studies like: 
 Solubility studies of drug in solvents 
 Angle of slide 
 Flowable liquid retention potential 
 Liquid load factor(LLf) 
 Liquid solid compressibility test 
Solubility Studies of Drug In Non Volatile Solvents 
To study the solubility a saturated solution must be 
prepared, this solution is prepared by adding excess amount 
of drug to the liquid and mixed with the help of a shaker at a 
given period of time under steady vibration. The filtrate so 
produced is used for analysis by spectrophotometry. 
Angle of Slide 
To determine the flow behaviour of the powder sliding angle 
is measured by  using a metallic plate with a smooth surface 
as a test where the powder is kept at one end and is 
increased in height till the plate is angular to horizontal 
plane where the powder can slide, an angle of 33° generally 
gives optimum flow properties. 
Flowable Liquid Retention  Potential 
It gives the potential of the liquid retention of the powder 
with an acceptable flow behaviour. 
Liquid Load Factor 
It can be determined by using adequate quantities of non 
volatile solvent and the drug is dissolved to produce a free 
flowing powder after the carrier and coating materials are 
added. It is given as the ratio of weight of liquid 
medication(W) to weight of carrier material(C). 
Liquisolid Compressibility Test 
The test is used to determine the compressible liquid 
retention value (ψ) by preparing an admixture of carrier and 
coating materials and converting them to tablets. The 
average liquid content of crushed tablets gives average 
rigidity. 
Evaluation of Liquisolid System 
 Flow behaviour 
 Differential scanning calorimetry 
 X-ray diffraction 
 Scanning electron microscopy 
 Dissolution testing 
 In-vivo evaluation 
Flow Behaviour  
Bulk Density 
The powder blend is weighed (W) and transferred into a 
measuring cylinder that is graded and the bulk volume (Vb) 
is calculated. Bulk density is determined by the formula 
                                   Bulk density = W/Vb 
Tapped Density 
The powder is weighed (W) and shifted into a graded 
measuring cylinder and tapped for a fixed number of times 
then the tapped volume (Vt) is measured. The tapped 
density is given as 
                                   Tapped density = W/Vt 
Compressibility Index 
Good flow properties are seen if compressibility index value 
is less than 15% and poor flow properties is seen if the 
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compressibility index value is more than 25%. 
Compressibility index is measured as 
     Compressibility index = (tapped density – bulk density) / 
tapped density × 100 
Hausner’s Ratio  
It varies depending on the choice of method selected to 
determine, hence it is not considered as a critical parameter. 
Good flow property indicates that the value is below 1.25 
and if it is above 1.5 it indicates poor flowability, it is 
estimated as 
Hausner’s ratio = tapped density/bulk density 
Angle of Repose 
It is determined by using a funnel where the powder is 
allowed to flow through the funnel till its tip touches the 
powder pile. It can be written as 
                                      Ø = tan-1 h/r 
Where,       h = height of pile 
                     r = radius of powder pile base 
Differential Scanning Calorimetry 
These DSC studies are used to assess the thermal behaviour 
of the liquisolid compacts and pure components. To 
determine the DSC 3 to 5mg of drug is vacuum packed in 
aluminium pans exposed to a temperature range of 30 to 
300°C. Vacant aluminium pans are used as reference and by 
purging nitrogen, the thermal  behaviour is studied. 
X-Ray Diffraction Studies 
XRD are used to determine the crystalline property of 
liquisolid compacts. These studies use a 30mA current and a 
copper target of voltage 40KV. The equipment generally 
works at an angle 5 to 70° and counting rate of 0.45/step. 
The peak pattern change tells about the conversion of drug 
nature from crystalline to amorphous. 
Scanning Electron Microscopy 
This method is used to know whether the drug is crystallised 
from the liquisolid system and also helps in measuring the 
surface behaviour of drug. These molecular forms can be 
disappeared due to the solubilising nature of the drug. 
In-Vitro Drug Release Studies 
USP dissolution apparatus type II is the apparatus used for 
the study of in-vitro drug release. Using this apparatus the 
studies are done in 900ml 0.1N HCl at constant temperature 
of 37°C±2 and at a stirring speed of 50 to 200 rmp[11]. The 
percentage of known amount of drug dissolved is measured 
by withdrawing samples at regular intervals and 
maintenance of sink conditions. 
In-Vivo Evaluation Of Liqisolid Tablets 
Peak plasma concentration, relative bioavailability and area 
under plasma concentration must show variable differences 
between the liquisolid compact and a commercial tablet. 
Applications 
 Drug Dissolution Can Be Improved: 
Drug dissolution rate is increased in low dose drugs 
like valsartan, famotidine etc. by the use of liquisolid 
technique. 
 Incorporation of High Dose Water Insoluble Drugs  
High dose less soluble drugs can be added to the 
system by simply incorporating additives like PVP, 
HPMC etc. As these additives can rise the liquid uptake 
of coating and carrier materials. Also addition of 
modern carriers show great capacity of absorption. 
 Sustained Drug Release 
It is a guaranteed method for producing sustained release 
drugs and also pH deviation. Control on drug release is 
decreased by using liquisolid technique, photo stability of 
drug in solid dosage form is also increased and this 
technique can be applied probiotics also. 
Conclusion 
Liquisolid technique is an approaching method for 
increasing the solubility and rate of dissolution thereby 
increasing the bioavailability and the extent of absorption of 
water-insoluble drugs compared to other conventional 
tablets using less production costs and simple 
manufacturing process. It is also used to formulate sustained 
release drugs and immediate release drugs by using 
hydrophobic and hydrophilic carriers. The drug release from 
liquisolid compacts is further enhanced by the use of 
disintegrant along with carriers and coating agents. Thus the 
selection of the excipients used like carriers, coating 
materials and detergents play a major role. Furthermore this 
technology has been truly favourable as the dissolution, 
bioavailability, solubility of most of the water-insoluble 
drugs has been enhanced to a noticeable value, especially to 
BCS class II and class IV drugs. 
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